retatrutide legal status A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity | European Journal of Clinical Pharmacology VisualAbstract: Retatrutide reduces body weight

The NEJM phase 2 obesity trial reports published retatrutide study design, dose groups, and safety findings

His skin cleared up

By combining prescribed medications with lifestyle guidance, we ensure that your weight management journey is as comfortable, effective, and sustainable as possible

Roles for Ghrelin in the Regulation of Appetite and Body Weight

Retatrutide has developed one of the most rapidly growing pre-clinical research profiles of any metabolic peptide currently in active study: Pre-clinical metabolic research in obese animal models has reported body weight and fat mass reductions with Retatrutide that exceed those observed with dual-receptor compounds including Tirzepatide at comparable doses and suggesting that the addition of glucagon receptor engagement to combined GLP-1/GIP agonism produces meaningfully greater metabolic effects in experimental settings